Hepatocellular carcinoma (HCC) · line 1 · Durvalumab + Tremelimumab (STRIDE)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-DURVA-TREME-STRIDE`

ID	`IND-HCC-SYSTEMIC-1L-DURVA-TREME`
Type	Indication
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-HCC`
Sources	`SRC-HIMALAYA-ABOU-ALFA-2022` `SRC-NCCN-HCC-2025`

Notes

Bev-sparing 1L track — variceal-bleed-history patients route here.

Used By

Algorithms

ALGO-HCC-SYSTEMIC-1L - ALGO-HCC-SYSTEMIC-1L